Labyrinthitis
diseaseOn this page
Also known as inflammation of internal earinternal ear inflammationotitis interna
Summary
Labyrinthitis (MONDO:0002008) is a disease (an umbrella term covering 6 Mondo subtypes) with 1 GWAS associations across 5 studies and 4 clinical trials. A subtype of inner ear disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 6 Mondo subtypes
- GWAS associations: 1
- Clinical trials: 4
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | labyrinthitis |
| Mondo ID | MONDO:0002008 |
| EFO | EFO:0009604 |
| MeSH | D007762 |
| DOID | DOID:1468, DOID:3930 |
| ICD-10-CM | H83.0 |
| ICD-11 | 901550793 |
| NCIT | C128369 |
| SNOMED CT | 23919004 |
| UMLS | C0022893 |
| MedGen | 5991 |
| Is cancer (heuristic) | no |
Also known as: inflammation of internal ear · internal ear inflammation · otitis interna
Data availability: 1 GWAS association (5 studies).
Disease family
This is a subtype of inner ear disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › auditory system disorder › inner ear disorder › labyrinthitis
Related subtypes (14): bilateral hyperactive labyrinth, labyrinthine bilateral reactive loss, labyrinthine unilateral reactive loss, unilateral hyperactive labyrinth, vestibular disorder, cochlear disorder, bilateral hypoactive labyrinth, unilateral hypoactive labyrinth, otosclerosis, motion sickness, X-linked mixed hearing loss with perilymphatic gusher, autoimmune inner ear disease, enlarged vestibular aqueduct syndrome, inner ear neoplasm
Subtypes (6): viral labyrinthitis, purulent labyrinthitis, focal labyrinthitis, toxic labyrinthitis, serous labyrinthitis, infectious otitis interna
Genetics & variants
GWAS landscape
1 GWAS associations across 5 studies. Top hits map to 1 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs2815603 | 9e-08 | CAMK1D | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90079944 | Backman JD | 2021 | 897 | 387,033 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90083930 | Backman JD | 2021 | 897 | 387,033 | Exome sequencing and analysis of 454,787 UK Biobank participants. |
| GCST90481960 | Verma A | 2024 | 783 | 447,600 | Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program. |
| GCST90436047 | Zhou W | 2018 | 767 | 402,827 | Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. |
| GCST90651820 | Liu TY | 2025 | 257 | 201,629 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 1 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 0 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs2815603 | 10 | 12479914 | C>T | 0.05 | intron_variant | CAMK1D | 9e-08 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 4.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 4 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05424302 | Not specified | RECRUITING | Effect of Peripheral Vestibular Disease Location on Outcomes Following Home-based Virtual Reality Vestibular Therapy |
| NCT01529151 | Not specified | COMPLETED | Effectiveness of Osteopathic Manipulative Treatment (OMT) and Vestibular Rehabilitation Therapy (VRT) in Individuals With Vertigo |
| NCT05052944 | Not specified | COMPLETED | Single-sided Deafness and Cochlear Implantation |
| NCT05157399 | Not specified | COMPLETED | Quantification of the Effect of the OtoBand on Objective Measures of Vertigo and Dizziness |
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.